Reshaping Workflows with Dell Pro Precision and NVIDIA RTX PRO GPUs

Contains several genuine operator insights - notably why productivity is hard to monetize vs. quality, the backlog/time-to-read value lever, and the foundation-model-vs-single-disease shift - but they're diluted by long host tangents and repetition.

“we thought it's going to be an efficiency play... productivity is very hard to effectively monetize”

“in the past you could do it, but you had to do it for one disease at a time”

The counterintuitive pivot from productivity to clinical quality as the monetizable value, and the 'Netflix originals + streaming service' framing for platform vs. models, are fresher than typical AI-hype takes, though the Bill Gates quote and general framing are recycled.

“everybody tells us nobody cares about quality”

“we have the Netflix streaming service and you have the Netflix originals”

Guest is a co-founder/CEO of Aidoc, a leading clinical AI company with the most FDA clearances in its category, and formerly headed an AI division at the Israeli Ministry of Defense - a genuine practitioner who has scaled the thing.

“I served in Israeli Ministry of Defense, headed an AI division”

“ADOC is a company with the most FDA clearances in the world for this category”

Strong on named customers and concrete numbers - 400,000 annual deaths, 18 FDA clearances, 99.7% specificity, Sutter's 12-month enterprise go-live, Wellspan's 200,000 cases, 1.6M patient studies - though a couple of figures are hedged as approximate.

“about every year we have about 400,000 deaths due to diagnostic error”

“The specificity, uh, of this was 99.7%, meaning the false positive rate was 0.3”

The host does land a few genuinely sharp challenges - the self-grading benchmark critique and the 'why train your own model when Claude exists' question - but these are surrounded by rambling tangents, personal anecdotes, and softball rapid-fire questions that let claims pass unchallenged.

“you've kind of set your own benchmark... have you one gotten any pushback”

“what is the strategic advantage other than you own the ip... Is it actually better on benchmarking stats?”